Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
p38 MAPK protein kinase inhibitor SCIO 469, 5 mg  

p38 MAPK protein kinase inhibitor SCIO 469, 5 mg

2-(6-chloro-5-((2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl)-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide

SCIO 469 is an orally available and selective inhibitor of p38 mitogen-activated protein (MAP) kinase (MAPK).
Synonyms: Talmapimod

More details

PKI-SCIO-005

Availability: within 3 days

156,00 €

Background: SCIO 469 / Talmapimod is an orally available and selective inhibitor of p38 mitogen-activated protein (MAP) kinase (MAPK), with a 10-fold selectivity for p38α over p38β and 2000-fold over 20 other kinases; potential agent with immunomodulating, anti-inflammatory and antineoplastic activities.

Chemical formula: C27H30ClFN4O3
Molecular weight: 513.00g/mol
Purity: 98%
Appearance: Yellow solid
Solubility: Soluble in DMSO
CAS Number: 309913-83-5

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

SN Nikas and AA Drosos. SCIO-469 Scios Inc. Curr Opin Investig Drugs. 2004, 5(11), 1205-1212.
 
SN Nikas and AA Drosos. SCIO-469 Scios Inc. Curr Opin Investig Drugs. 2004, 5(11), 1205-1212.
 
T Navas et al. The p38 MAPK inhibitor SCIO-469 enhances the apoptotic and anti-proliferative effects of proteasome inhibitors MG132 and PS341 (Velcade) in multiple myeloma cells. Proc. Amer. Assoc. Cancer Res, 2004, Vol. Abs. #3350.

The following products could also be interesting for you: